The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
Promising effects beyond weight loss Researchers are currently studying the effect of GLP-1s on a wide range of conditions beyond diabetes, obesity, and heart disease, including renal, hepatic, neurological, and substance-use disorders
Your doctor can call Eli Lilly at 1-800-545-5979, and the company responds within 5 business days
According to a recent report by Morgan Stanley, the global market for obesity drugs is expected to increase 15-fold by 2030, driven by their expanding use beyond weight loss to address various obesity-related conditions
"Reactivate Your GLP-1" is brand-stated marketing language published by GLPro at glpatch.shop - not a verified physiological claim by this publication